Articles tagged "Induction therapy"

2020 American Transplant Congress
Pancreas Transplant in Patients Older Than 50: An Analysis of Outcomes and Immunosuppression
I. Booth¹, J. Casale¹, S. Freedman¹, B. Ravichandran¹, J. Scalea², A. Haririan², B. Masters¹
¹Pharmacy, University of Maryland Medical Center, Baltimore, MD, ²Medicine, University of Maryland Medical Center, Baltimore, MD
*Purpose: Pancreas transplant (PT) is the ideal therapy for many patients with diabetes and kidney failure. There are limited published data addressing the impact of…
2020 American Transplant Congress
Low-Dose Rabbit Antithymocyte Globulin Induction in Elderly Kidney Transplant Recipients at High Immunologic Risk is Safe and May Prevent Excess Rejection
E. Sartain¹, B. Nettles¹, B. Crowther¹, P. Klem¹, K. Schwarz¹, S. Davis²
¹University of Colorado Hospital, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO
*Purpose: Patients aged ≥65 years are a growing segment of kidney transplant recipients (KTRs). Consensus on induction immunosuppression in this population is unclear given higher…
2020 American Transplant Congress
Impact of Alemtuzumab Induction on Cardiac Allograft Vasculopathy in Orthotopic Heart Transplant Recipients
M. Plazak¹, X. Gao², S. Gale², B. Reed², R. Madathil¹, S. Hammad¹, B. Ravichandran¹
¹University of Maryland Medical Center, Baltimore, MD, ²University of Maryland School of Pharmacy, Baltimore, MD
*Purpose: Cardiac allograft vasculopathy (CAV) is impacted by acute rejection and ultimately limits long-term survival of orthotopic heart transplant (OHT) recipients, thus there is interest…
2020 American Transplant Congress
Anti-Thymocyte Globulins Induced Immunomodulatory Effect and Increased Regulatory T Cell in a In Vitro Model of Allogeneic Cell Coculture
M. Colladant¹, J. Lion², P. Saas³, S. Perruche³, D. Ducloux¹, N. Mooney², J. Bamoulid¹
¹Nephrologie, Dialyse et Transplantation, CHU de Besançon, Besancon, France, ²Equipe INSERM: Endothelium, Inflammation et Alloreactivity INSERM UMR-S 976, Paris, France, ³INSERM U1098 RIGHT, Université de Franche-Comté EFS Bourgogne Franche-Comté, Besancon, France
*Purpose: Two types of Anti-Thymocyte Globulins (ATG) are commonly used in renal transplantation (Thymoglobuline and Grafalon) and induce severe, dose-dependent and sometimes persistent CD4+ T…
2020 American Transplant Congress
Anti-Thymocyte Globulin versus Interleukin-2 Receptor Antagonist and Deceased-Donor Kidney Transplant Outcomes among Older Recipients
J. Ahn¹, S. Bae¹, K. Lentine², M. Schnitzler², G. Hess³, D. Segev¹, M. McAdams-DeMarco¹
¹Johns Hopkins University, Baltimore, MD, ²Saint Louis University, St. Louis, MO, ³Drexel University, Philadelphia, PA
*Purpose: Kidney transplantation (KT) has been growing treatment option for older end-stage renal disease patients. Although lymphocyte-depleting agents are considered to be superior than interleukin-2…
2020 American Transplant Congress
Safety Outcomes in Lower-Weight vs Higher-Weight Recipients of Fixed Dose Alemtuzumab for Kidney Transplant Induction
A. Freeman, S. Anders, B. Wise, M. Janusek, L. Hutchinson, U. Kaszubski, D. Marroquin, D. Martin, H. Bohorquez
Ochsner Medical Center, New Orleans, LA
*Purpose: Alemtuzumab is a lymphocyte-depleting monoclonal antibody used for renal transplant induction, and is associated with significant leukopenia, increased infections and malignancy. Multiple dosing strategies…
2020 American Transplant Congress
Ten Year Results of a Single Center Study of Rabbit Anti-Thymocyte Globulin Compared to Alemtuzumab Induction in Simultaneous Pancreas-Kidney Transplantation
V. Gurram, K. Gurung, G. Orlando, A. Farney, J. Rogers, C. Jay, W. Doares, S. Kaczmorski, A. Reeves-Daniel, A. Mena-Gutierrez, M. Gautreaux, R. Stratta
Abdominal Transplant Surgery, Wake Forest Baptist Health, Winston Salem, NC
*Purpose: The study purpose was to analyze 10-year outcomes of depleting antibody induction agents in simultaneous pancreas-kidney transplant (SPKT) at a single center*Methods: From 2/02…
2020 American Transplant Congress
The FcγRIIIa-158 VV Genotype Increased the Risk of Post-Transplant Lymphoproliferative Disorder in T-Cell Depleted Kidney Transplant Recipients
P. Gatault¹, L. Lajoie¹, J. Stojanova², P. Marquet², G. Thibault¹
¹CHU Tours, Tours, France, ²CHU Limoges, Limoges, France
*Purpose: Post-transplantation lymphoproliferative disorder (PTLD) is a severe complication in organ transplant recipients. The use of T lymphocyte-depleting antibodies (TLDAb), especially rabbit TLDAb contributes to…
2020 American Transplant Congress
Comparative Study between ATG and Grafalon as Induction Agent in Renal Transplant Recipient
L. K. Das, P. Paudyal, S. Shrestha, B. Shahi, A. Pandey, R. Verma, P. Chandra Shrestha
Kidney and Liver Transplant, Shahid Dharmabhakta National Transplant Center, Kathmandu, Nepal
*Purpose: Renal transplantation (Rtx) remains the most effective treatment for of end-stage renal disease (ESRD). The development of induction therapy has significantly reduced the incidence…
2020 American Transplant Congress
Donor-Derived Cell-Free DNA Levels During Early Rejection after Kidney Transplant May Be Impacted by Type of Induction Agent Received
M. Gillespie, K. Lim, A. Vo, E. Huang, N. Ammerman, A. Peng, R. Najjar, S. Sethi, S. Jordan
Cedars-Sinai, Los Angeles, CA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is an injury biomarker that detects rejection in kidney transplant recipients (KTR). It is reported as % cfDNA from the…